(Q38345576)

2 September 2017

1 reference

title

Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma (English)

1 reference

chronic lymphocytic leukemia and small lymphocytic lymphoma

2 September 2017

0 references

0 references

author name string

Clare Sun

series ordinal

1

1 reference

2 September 2017

Adrian Wiestner

series ordinal

2

1 reference

2 September 2017

publication date

1 January 2015

1 reference

Cancer Treatment and Research

2 September 2017

published in

1 reference

2 September 2017

volume

165

1 reference

2 September 2017

page(s)

147-175

1 reference

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

NOTCH1 mutations in CLL associated with trisomy 12.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The role of minimal residual disease measurements in the therapy for CLL: is it ready for prime time?

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

B cell receptor signaling in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

miR-15 and miR-16 induce apoptosis by targeting BCL2

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Adhesion receptors on peripheral blood leukemic B cells. A comparative study on B cell chronic lymphocytic leukemia and related lymphoma/leukemias

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Fibronectin interaction with α4β1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Genomic aberrations and survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The effect of immunoglobulinVH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Immunological aspects in chronic lymphocytic leukemia (CLL) development

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Structure of the integrin VLA-4 and its cell-cell and cell-matrix adhesion functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Adhesion of ZAP-70+ chronic lymphocytic leukemia cells to stromal cells is enhanced by cytokines and blocked by inhibitors of the PI3-kinase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Adhesion to bone marrow stroma inhibits apoptosis of chronic lymphocytic leukemia cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

HLA-identical sibling bone marrow transplantation in younger patients with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

B-cell receptor signaling as a driver of lymphoma development and evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Rituximab dose-escalation trial in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression and prognosis in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

4 1 integrin and 190-kDa CD44v constitute a cell surface docking complex for gelatinase B/MMP-9 in chronic leukemic but not in normal B cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL)

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Alpha4 integrins and the immune response

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the Cooperative German Transplant Study Group.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chronic lymphocytic leukemia: revelations from the B-cell receptor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ABT-199 selectively inhibits BCL2 but not BCL2L1 and efficiently induces apoptosis of chronic lymphocytic leukaemic cells but not platelets.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Diversity in the CDR3 region of V(H) is sufficient for most antibody specificities

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

Targeting pathological B cell receptor signalling in lymphoid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

ZAP-70 expression is associated with increased risk of autoimmune cytopenias in CLL patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

TP53 mutation and survival in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-13150-4_6

10.1007/978-3-319-13150-4_6

31 March 2020

Identifiers

DOI

1 reference

2 September 2017

1 reference